Pear Therapeutics Inc:企業の製品パイプライン分析2018

◆英語タイトル:Pear Therapeutics Inc - Product Pipeline Analysis, 2018 Update
◆商品コード:DATA904C12777
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD1,500 ⇒換算¥163,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥245,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive designed for schizophrenia; reCALL using virtual reality exposure therapy to treat combat posttraumatic stress disorder (PTSD); reVIVE against general anxiety disorder; and PEAR-005 to PEAR-011 for treating pain, major depressive disorder, insomnia, Parkinson’s disease and inflammatory conditions. Pear Therapeutics reSET, is an FDA-authorized prescription therapeutic for substance use disorder (SUD) used as an outpatient treatment. The company works in partnership with Center for Technology and Behavioral Health, Dartmouth College, Ehave, Inc., Intellectual Ventures Management LLC, Novartis AG, and others. Pear Therapeutics is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Pear Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pear Therapeutics Inc Company Overview 5
Pear Therapeutics Inc Company Snapshot 5
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Pear Therapeutics Inc – Pipeline Analysis Overview 8
Pear Therapeutics Inc – Key Facts 8
Pear Therapeutics Inc – Major Products and Services 9
Pear Therapeutics Inc Pipeline Products by Development Stage 11
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Pear Therapeutics Inc Pipeline Products Overview 15
Digital Therapeutic – Inflammatory conditions 15
Digital Therapeutic – Inflammatory conditions Product Overview 15
Digital Therapeutic – Major Depressive Disorder 16
Digital Therapeutic – Major Depressive Disorder Product Overview 16
Digital Therapeutic – Oncology 17
Digital Therapeutic – Oncology Product Overview 17
Digital Therapeutic – Parkinson’s Disease 18
Digital Therapeutic – Parkinson’s Disease Product Overview 18
Digital Therapeutic – Respiratory 19
Digital Therapeutic – Respiratory Product Overview 19
PEAR-003 – Insomnia 20
PEAR-003 – Insomnia Product Overview 20
PEAR-006 – Multiple Sclerosis 21
PEAR-006 – Multiple Sclerosis Product Overview 21
reCALL 22
reCALL Product Overview 22
reVIVE 23
reVIVE Product Overview 23
Thrive 24
Thrive Product Overview 24
Thrive Clinical Trial 25
Pear Therapeutics Inc – Key Competitors 26
Pear Therapeutics Inc – Key Employees 27
Pear Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Pear Therapeutics Inc, Recent Developments 29
Jan 16, 2018: Magellan Health Continues Innovation and Efforts to Improve Outcomes for Patients with Substance Use Disorder 29
Dec 12, 2017: Pear Therapeutics Wins Fierce Innovation Life Science Award for reSET Prescription Digital Therapeutic 29
Oct 18, 2017: Pear Therapeutics Receives Expedited Access Pathway Designation from FDA for reSET-O Prescription Digital Therapeutic to Treat Opioid Use Disorder 30
Sep 26, 2017: Pear Therapeutics Selected to Participate in the FDA’s Digital Health Software Pre-Cert Pilot Program 30
Sep 14, 2017: FDA permits marketing of mobile medical application for substance use disorder 31
Sep 14, 2017: Pear Therapeutics Obtains FDA Clearance Of The First Prescription Digital Therapeutic To Treat Disease 31
Jul 11, 2017: Enhancing Digital Medicine to Tackle Addiction 32
Aug 25, 2016: The Largest and Longest Study of Patients with Schizophrenia Interacting with Digital Therapeutics Results Released 33
Appendix 34
Methodology 34
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Pear Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 5
Pear Therapeutics Inc Pipeline Products by Equipment Type 6
Pear Therapeutics Inc Pipeline Products by Indication 7
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 7
Pear Therapeutics Inc, Key Facts 8
Pear Therapeutics Inc, Major Products and Services 9
Pear Therapeutics Inc Number of Pipeline Products by Development Stage 11
Pear Therapeutics Inc Pipeline Products Summary by Development Stage 12
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Pear Therapeutics Inc Ongoing Clinical Trials Summary 14
Digital Therapeutic - Inflammatory conditions - Product Status 15
Digital Therapeutic - Inflammatory conditions - Product Description 15
Digital Therapeutic - Major Depressive Disorder - Product Status 16
Digital Therapeutic - Major Depressive Disorder - Product Description 16
Digital Therapeutic - Oncology - Product Status 17
Digital Therapeutic - Oncology - Product Description 17
Digital Therapeutic - Parkinson's Disease - Product Status 18
Digital Therapeutic - Parkinson's Disease - Product Description 18
Digital Therapeutic - Respiratory - Product Status 19
Digital Therapeutic - Respiratory - Product Description 19
PEAR-003 - Insomnia - Product Status 20
PEAR-003 - Insomnia - Product Description 20
PEAR-006 - Multiple Sclerosis - Product Status 21
PEAR-006 - Multiple Sclerosis - Product Description 21
reCALL - Product Status 22
reCALL - Product Description 22
reVIVE - Product Status 23
reVIVE - Product Description 23
Thrive - Product Status 24
Thrive - Product Description 24
Thrive - A Randomized, Sham-controlled Study of PEAR-004 as an Adjunct to Standard-of-care Treatment for Schizophrenia 25
Pear Therapeutics Inc, Key Employees 27
Pear Therapeutics Inc, Other Locations 28
Glossary 36

List of Figures
Pear Therapeutics Inc Pipeline Products by Equipment Type 6
Pear Therapeutics Inc Pipeline Products by Development Stage 11
Pear Therapeutics Inc Ongoing Clinical Trials by Trial Status 13

★海外企業調査レポート[Pear Therapeutics Inc:企業の製品パイプライン分析2018]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Almac Group Ltd:企業のM&A・事業提携・投資動向
    Almac Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Almac Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • NSD Co., Ltd. (9759):企業の財務及び戦略的SWOT分析
    Summary NSD Co., Ltd. (NSD) is a technology solution company that provides integrated information technology consulting services. The company provides services such as system analysis and design, customized development of software programs administration of facilities management, and packaged softwa …
  • Ludwig Institute For Cancer Research Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Ludwig Institute for Cancer Research Ltd (LICR) is a non-profit organization that conducts cancer research and clinical trial programs. The organization carries out research in the areas of clinical trials, genomics, cell biology, immunology, neuroscience, signaling, therapeutics, stem cells …
  • SeLoger.com SA:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' SeLoger.com SA Mergers and Acqu …
  • Telecom Italia S.p.A.:企業の戦略・SWOT・財務分析
    SummaryTelecom Italia S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key F …
  • Sasol Ltd (SOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Sasol Ltd (Sasol) is an integrated energy and chemicals company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and …
  • Avesthagen Limited:企業のM&A・提携動向(医療機器分野)
    Summary Avesthagen Limited (Avesthagen) is a life science company that offers preventive personalized healthcare solutions. The company offers bio-nutrition, bio-agriculture and bio-pharmaceutical products. Its bio-nutrition products include validated bio-actives from Indian medicinal plants for pre …
  • Nord Gold N.V.:企業の戦略・SWOT・財務分析
    Nord Gold N.V. - Strategy, SWOT and Corporate Finance Report Summary Nord Gold N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SCHOTT Solar AG(エネルギー分野):企業M&A動向
    Summary SCHOTT Solar AG (SCHOTT Solar), a subsidiary of SCHOTT Group, develops, manufactures and markets receivers, a crucial component of concentrated solar power plants. The Schott solar CSP receivers offer SCHOTT PTR70 Receiver Platform and fourth generation receiver. The company uses parabolic t …
  • Gerdau S.A.:企業のM&A・提携・投資分析
    Gerdau S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gerdau S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • B.O.S. Better OnLine Solutions Ltd. (BOSC):企業概要、財務及び戦略的SWOT分析
    Summary B.O.S. Better OnLine Solutions Ltd. (B.O.S) is healthcare IT company. The company provides RFID, mobile and supply chain solutions for logistics and organizational processes. It provides comprehensive automatic identification data capture (AIDC), radio frequency identification (RFID) and mob …
  • Russian Helicopters JSC:企業の戦略・SWOT・財務分析
    SummaryRussian Helicopters JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key …
  • Skye Bank Plc:企業の戦略・SWOT・財務分析
    SummarySkye Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings …
  • Kodama Chemical Industry Co. Ltd. (4222):企業の財務及び戦略的SWOT分析
    Summary Kodama Chemical Industry Co. Ltd. (Kodama Chemical) is a plastic products manufacturer that manufactures and sells plastic molded and plastic molding processed products. The company’s machinery device segment manufactures and sells processing machines for plastic molded articles, trades plas …
  • Cobham plc:企業の戦略・SWOT・財務情報
    Cobham plc - Strategy, SWOT and Corporate Finance Report Summary Cobham plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Credit Suisse Group AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Credit Suisse Group AG Mergers …
  • CMA CGM SA:企業の戦略・SWOT・財務情報
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Thesan Pharmaceuticals Inc:企業のM&A・提携動向(医療分野)
    Summary Thesan Pharmaceuticals Inc (Thesan Pharmaceuticals) is a biopharmaceutical company that focuses on the development of novel therapeutics for the treatment of dermatological disorders. The company’s product line includes ARN-077: Pain, Wounds and Bed Sores, Drug: Atopic Dermatitis, and Drug: …
  • DaVita Inc (DVA):医療機器:M&Aディール及び事業提携情報
    Summary DaVita Inc (DaVita), formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and end-stage renal disease (ESRD). …
  • Gran Tierra Energy Inc.:企業のM&A・提携・投資分析
    Gran Tierra Energy Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gran Tierra Energy Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆